BR112014016950A8 - métodos de promoção da cicatrização de úlceras diabéticas utilizando beta-hidróxi-beta-metilbutirato com arginina e glutamina - Google Patents

métodos de promoção da cicatrização de úlceras diabéticas utilizando beta-hidróxi-beta-metilbutirato com arginina e glutamina

Info

Publication number
BR112014016950A8
BR112014016950A8 BR112014016950A BR112014016950A BR112014016950A8 BR 112014016950 A8 BR112014016950 A8 BR 112014016950A8 BR 112014016950 A BR112014016950 A BR 112014016950A BR 112014016950 A BR112014016950 A BR 112014016950A BR 112014016950 A8 BR112014016950 A8 BR 112014016950A8
Authority
BR
Brazil
Prior art keywords
beta
methylbutyrate
glutamine
arginine
hydroxy
Prior art date
Application number
BR112014016950A
Other languages
English (en)
Other versions
BR112014016950A2 (pt
Inventor
C Voss Anne
L Paule Charles
Suarez Fabrizis
Fanjiang Gary
L Nelson Jeffrey
G Baggs Maria
A Hegazi Refaat
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47561872&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014016950(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR112014016950A2 publication Critical patent/BR112014016950A2/pt
Publication of BR112014016950A8 publication Critical patent/BR112014016950A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

resumo “métodos de promoção da cicatrização de úlceras diabéticas utilizando beta-hidróxi-beta-metilbutirato com arginina e glutamina” é divulgada a combinação de beta-hidróxi-beta-metilbutirato, arginina e glutamina para uso em um método de tratamento de uma úlcera diabética em um indivíduo diabético que possui pelo menos um de: (a) um nível de albumina no soro menor que ou igual a 4,0 g/dl e/ou (b) um índice tornozelo-braquial menor que 1,0. 9. também é divulgado o uso da combinação de beta-hidróxi-beta-metilbutirato, arginina e glutamina para a produção de um medicamento para uso no tratamento de uma úlcera diabética em um indivíduo diabético que possui pelo menos um de: (a) um nível de albumina no soro menor que ou igual a 4,0 g/dl e/ou (b) um índice tornozelo-braquial menor que 1,0. em certas modalidades, a combinação de beta-hidróxi-beta-metilbutirato, arginina e glutamina é administrada oralmente através de uma composição nutricional.
BR112014016950A 2012-01-11 2013-01-10 métodos de promoção da cicatrização de úlceras diabéticas utilizando beta-hidróxi-beta-metilbutirato com arginina e glutamina BR112014016950A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261585265P 2012-01-11 2012-01-11
PCT/US2013/021029 WO2013106570A1 (en) 2012-01-11 2013-01-10 Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers

Publications (2)

Publication Number Publication Date
BR112014016950A2 BR112014016950A2 (pt) 2017-06-13
BR112014016950A8 true BR112014016950A8 (pt) 2017-07-04

Family

ID=47561872

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014016950A BR112014016950A8 (pt) 2012-01-11 2013-01-10 métodos de promoção da cicatrização de úlceras diabéticas utilizando beta-hidróxi-beta-metilbutirato com arginina e glutamina

Country Status (13)

Country Link
US (1) US10064835B2 (pt)
EP (1) EP2802322B1 (pt)
JP (2) JP2015503619A (pt)
CN (1) CN104302285A (pt)
BR (1) BR112014016950A8 (pt)
CA (1) CA2860642C (pt)
ES (1) ES2668885T3 (pt)
HK (1) HK1203822A1 (pt)
MX (1) MX2014008521A (pt)
PH (1) PH12014501579A1 (pt)
SG (1) SG11201403951UA (pt)
TW (1) TWI592153B (pt)
WO (1) WO2013106570A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860642C (en) 2012-01-11 2016-11-01 Abbott Laboratories Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers
DE102018124227A1 (de) 2018-10-01 2020-04-02 sanaFactur GmbH Zubereitung zur Verbesserung körpereigener Wundheilung
WO2022177516A1 (en) * 2021-02-17 2022-08-25 Montero Gida Sanayi Ve Ticaret Anonim Sirketi Nutritional powder compositions for promoting wound healing
WO2022225779A1 (en) 2021-04-19 2022-10-27 Abbott Laboratories Methods and compositions for promoting wound healing
WO2023027859A1 (en) * 2021-08-26 2023-03-02 Abbott Laboratories Methods and compositions for improving wound healing
CN115067518A (zh) * 2022-06-07 2022-09-20 广东特芯生物科技有限公司 一种用于提高肿瘤患者免疫力的组合物
CN115040550A (zh) * 2022-06-07 2022-09-13 广东特芯生物科技有限公司 一种用于提高免疫球蛋白g的组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
CA2860642C (en) 2012-01-11 2016-11-01 Abbott Laboratories Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers

Also Published As

Publication number Publication date
EP2802322A1 (en) 2014-11-19
US20150133548A1 (en) 2015-05-14
SG11201403951UA (en) 2014-08-28
TW201334774A (zh) 2013-09-01
CA2860642C (en) 2016-11-01
EP2802322B1 (en) 2018-02-28
JP2018076320A (ja) 2018-05-17
BR112014016950A2 (pt) 2017-06-13
CA2860642A1 (en) 2013-07-18
TWI592153B (zh) 2017-07-21
CN104302285A (zh) 2015-01-21
PH12014501579A1 (en) 2014-10-08
MX2014008521A (es) 2014-08-21
US10064835B2 (en) 2018-09-04
ES2668885T3 (es) 2018-05-22
WO2013106570A1 (en) 2013-07-18
HK1203822A1 (en) 2015-11-06
JP2015503619A (ja) 2015-02-02

Similar Documents

Publication Publication Date Title
BR112014016950A8 (pt) métodos de promoção da cicatrização de úlceras diabéticas utilizando beta-hidróxi-beta-metilbutirato com arginina e glutamina
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112012012476A2 (pt) "composições nutritivas incluindo um componente de alta proteína e nucleotídeos exôgenos"
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
BR112015005048A8 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112013027119A8 (pt) novos conjugados ligante-droga (adcs) e uso dos mesmos
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
BR112015019066A2 (pt) Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
BR112014010417A2 (pt) Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina
BR112015002372A2 (pt) composições e métodos para a redução do teor de álcool no sangue
BR112015024926A2 (pt) composições, artigo de fabricação, métodos para tratar um paciente com câncer, para avaliar uma composição, para avaliar a atividade biológica, para produzir uma composição e para avaliar a fragmentação de uma composição e variante de pertuzumabe
BR112012013487A2 (pt) Composições de amantadina e métodos de uso
CL2009000757A1 (es) Compuestos derivados de 6,8,2´-tris-(isobut-2-en-1-il)-diosmetina; procedimientos para su elaboracion; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades venosas cronicas, sindrome post-trombotico, complicaciones vasculares ligadas a la diabetes, entre otras.
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112016007487A2 (pt) composições compreendendo citrulina e leucina e seu uso no tratamento de diabetes e de síndrome meta-bólica
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
BR112017010453A2 (pt) composição adesiva com mudança de cor
BR112015000616A2 (pt) tratamento da esclerose múltipla com combinação de laquinimode e fampridina
BR112013010325A2 (pt) composições para o tratamento de úlceras periféricas de várias origens
BR112015001859A2 (pt) tratamento de inflamação utilizando serelaxina
BR112018008893A8 (pt) método para tratamento ou amenização de sintomas em um indivíduo com uma doença associada a um nervo craniano em particular, e composição farmacêutica óptica
BR112013009660A2 (pt) proteína de fusão com fator de atividade ix

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]